Journals / Klinik Psikofarmakoloji Bülteni / 2013 / Cilt: 23 - Sayı: 3

Paliperidon ER bağlı geç diskinezi

Paliperidone ER-induced tardive dyskinesia

Pages
264–266
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although atypical antipsychotics have a low risk for movement disorder related events, paliperidone ER does not seem to be lacking in such adverse effects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The evidence suggests a lower tardive dyskinesia risk associated with atypical antipsychotics.
📊
Key Findings & Data:Tardive perioral dyskinesia developed in patients at the ninth and twelfth months of paliperidone ER treatment (12 mg/day and 9 mg/day, respectively).
💡
Conclusion & Impact:Although atypical antipsychotics have a low risk for movement disorder related events, paliperidone ER does not seem to be lacking in such adverse effects.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The evidence suggests a lower tardive dyskinesia risk associated with atypical antipsychotics. We present two adult female cases with tardive dyskinesia. Tardive perioral dyskinesia developed in patients at the ninth and twelfth months of paliperidone ER treatment (12 mg/day and 9 mg/day, respectively). These symptoms were improved after switching to quetiapine 800 mg/day in the first patient while lowering the dose of paliperidone ER to 6 mg/day resulted in significant improvement in the second patient. Although atypical antipsychotics have a low risk for movement disorder related events, paliperidone ER does not seem to be lacking in such adverse effects.

Özet

Kanıtlar atipik antipsikotik kullanımının daha az geç dis-kinezi oluşturduğunu öne sürmektedir. Biz iki geç dis- kinezi olgusu sunmaktayız. Olgularımızda geç perioral diskinezi, paliperidon ER kullanımının 9. ve 12. aylarında gelişmiştir (sırasıyla 12 mg/gün ve 9 mg/gün dozlarda).Bu semptomlar birinci olguda ketiapin 800 mg/günkullanımına değiştirilerek, ikinci olguda ise paliperidondozunun 6 mg/gün’e azaltılması ile iyileşmiştir. Atipikantipsikotikler hareket bozuklukları ile ilişkili düşükriskli olarak bilinmesine rağmen paliperidon kullanımıile bu yan etki gözlenebilmektedir.

🔖

Cite This Article

YANARTAS, O., YILMAZ, Y., SAYGILI, I., BOZKURT, S. Z., SEMİZ, U. B. (2022). Paliperidon ER bağlı geç diskinezi. Klinik Psikofarmakoloji Bülteni, Cilt: 23 - Sayı: 3, 264–266. https://ajindex.com/articles/574059

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007;21(11):911-36
  2. Kulkarni SK, Naidu PS. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today (Barc) 2003;39(1):19-49
  3. Ugurlu GK, Tufan E, Bilici R, Ugurlu M, Saglam S. Olanzapine induced tardive dyskinesia treated successfully with quetiapine: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(1):276-7
  4. Wei HT, Lai YW, Chen MH, Chen YS. Oral-paliperidone- induced tardive dyskinesia: a case report. Gen Hosp Psychiatry 2011 Dec 8. (Epub ahead of print
  5. Harrington CA, English C. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. Int Clin Psychopharmacol 2010;25(6):334-41
  6. Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol 2010;30(5):531-40. 7. de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 2010;51(1):80-8
  7. Hüther R, Gebhart C, Mirisch S, Bäuml J, Förstl H. Choreatic symptoms during and after treatment with paliperidone and escitalopram. Pharmacopsychiatry 2008;41(5):203-4
  8. Teng PR, Lai TJ. Paliperidone-related rabbit syndrome. J Clin Psychopharmacol 2011;31(3):379-80
  9. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo- controlled trial. Schizophr Res 2007;90(1-3):147-61
  10. Karamustafalioglu KO. New Horizons in the treatment of schizophrenia: Palliperidone. Klinik Psikofarmakoloji Bulteni -Bulletin of Clinical Psychopharmacology 2009;19(Suppl 2):S341-S42
  11. Gardos G & Cole JO. The treatment of tardive dyskinesias. In: Bloom FE, Kupfer DJ eds. Psychopharmacology: the fourth generation of progress New York: Raven Press, 1995:1503-11
  12. Peritogiannis V, Tsouli S. Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature. J Psychopharmacol 2010;24(7):1121-5
  13. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997;23(4):583-609
  14. Kimiagar I, Dobronevsky E, Prokhorov T, Miniovitz A, Rabey JM. Rapid improvement of tardive dyskinesia with tetrabenazine,